Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Public ClinicalTrials.gov record NCT02811783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Study identification
- NCT ID
- NCT02811783
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Elorac, Inc.
- Industry
- Enrollment
- 59 participants
Conditions and interventions
Interventions
- Naloxone Hydrochloride Lotion, 0.5% Drug
- Placebo Lotion Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2016
- Primary completion
- Aug 31, 2022
- Completion
- Aug 31, 2022
- Last update posted
- Oct 27, 2022
2017 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| City of Hope | Duarte | California | 91010 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| USSF Health Morsani Center for Advanced Healthcare | Tampa | Florida | 33612 | — |
| Cleveland Clinic Indian River Hospital | Vero Beach | Florida | 32960 | — |
| Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| St. Louis University Dermatology | St Louis | Missouri | 63104 | — |
| Washington University School of Medicine St. Louis | St Louis | Missouri | 63110 | — |
| Stony Brook Dermatology | Stony Brook | New York | 11790 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| University of Washington / Seattle Cancer Care Alliance (SCCA) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02811783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02811783 live on ClinicalTrials.gov.